A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Group B Strep DNA by PCR
MessageTHIS TEST IS NOT INTENDED TO DIFFERENTIATE CARRIERS OF GROUP B STREPTOCOCCUS FROM THOSE WITH STREPTOCOCCAL DISEASE.
Test Code
CPT Codes
87653
Preferred Specimen
VAGINAL/RECTAL
Instructions
COLLECT VAGINAL AND RECTAL SWAB SPECIMEN USING THE CDC RECOMMENDED CLINICAL PROCEDURE.
Transport Container
BD CULTURETTE SWAB DEVICE
Transport Temperature
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Methodology
Real-Time Polymerase Chain Reaction (RT-PCR)
Setup Schedule
TWICE DAILY MONDAY-FRIDAY (10 AM/ 10 PM)
ONCE DAILY SATURDAY, SUNDAY, AND HOLIDAYS (NOON)
Report Available
Reference Range
NEGATIVE
Clinical Significance
Group B Streptococcus (GBS) is a Gram positive bacterium found in the lower intestinal tract of 10-30% of all healthy adults. A person who carries GBS but does not show signs of GBS disease is said to be “colonized” with GBS.
GBS can cause severe disease in a newborn and is known to be a leading cause of life threatening bacterial infections in newborns. A number of strains of the pathogen circulate in the community, and approximately 80% of newborn infections are acquired during birth by vertical (mother-to-baby) transmission. Of those infected, 25% incur serious long-term consequences such as deafness, blindness and neurological damage. Approximately 100 babies die annually in the U.S. in the first three months of life as a result of GBS infection and half of these deaths occur during the first week of life.
The current standard of care for preventing neonatal GBS disease is screening pregnant women at 35-37 weeks of gestation to determine their GBS colonization status.